Last reviewed · How we verify
Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer (NAPAN)
To determine the optimal second line treatment strategy in patients with metastatic pancreatic cancer who underwent a therapy with gemcitabine.
Details
| Lead sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
|---|---|
| Phase | PHASE2 |
| Status | UNKNOWN |
| Enrolment | 122 |
| Start date | Sun Dec 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sat Jan 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Metastatic Pancreatic Cancer
Interventions
- S1 + Nal-IRI
- Nal-IRI+Leucovorin+5-FU
Countries
Netherlands